182 related articles for article (PubMed ID: 16439521)
1. Generation of CD8+ T-cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1 Env.
Cayabyab MJ; Hovav AH; Hsu T; Krivulka GR; Lifton MA; Gorgone DA; Fennelly GJ; Haynes BF; Jacobs WR; Letvin NL
J Virol; 2006 Feb; 80(4):1645-52. PubMed ID: 16439521
[TBL] [Abstract][Full Text] [Related]
2. Rapid memory CD8+ T-lymphocyte induction through priming with recombinant Mycobacterium smegmatis.
Hovav AH; Cayabyab MJ; Panas MW; Santra S; Greenland J; Geiben R; Haynes BF; Jacobs WR; Letvin NL
J Virol; 2007 Jan; 81(1):74-83. PubMed ID: 17050608
[TBL] [Abstract][Full Text] [Related]
3. Generation of mucosal anti-human immunodeficiency virus type 1 T-cell responses by recombinant Mycobacterium smegmatis.
Yu JS; Peacock JW; Vanleeuwen S; Hsu T; Jacobs WR; Cayabyab MJ; Letvin NL; Frothingham R; Staats HF; Liao HX; Haynes BF
Clin Vaccine Immunol; 2006 Nov; 13(11):1204-11. PubMed ID: 16943347
[TBL] [Abstract][Full Text] [Related]
4. Genetic alteration of Mycobacterium smegmatis to improve mycobacterium-mediated transfer of plasmid DNA into mammalian cells and DNA immunization.
Mo Y; Quanquin NM; Vecino WH; Ranganathan UD; Tesfa L; Bourn W; Derbyshire KM; Letvin NL; Jacobs WR; Fennelly GJ
Infect Immun; 2007 Oct; 75(10):4804-16. PubMed ID: 17664267
[TBL] [Abstract][Full Text] [Related]
5. Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120.
Wang X; Uto T; Akagi T; Akashi M; Baba M
J Virol; 2007 Sep; 81(18):10009-16. PubMed ID: 17609261
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of HIV-1 Env-Specific CD8 T Cell Responses Using Interferon-Stimulated Gene 15 as an Immune Adjuvant.
Gómez CE; Perdiguero B; Falqui M; Marín MQ; Bécares M; Sorzano CÓS; García-Arriaza J; Esteban M; Guerra S
J Virol; 2020 Dec; 95(2):. PubMed ID: 33115866
[TBL] [Abstract][Full Text] [Related]
7. Recombinant Mycobacterium bovis bacillus Calmette-Guerin elicits human immunodeficiency virus type 1 envelope-specific T lymphocytes at mucosal sites.
Yu JS; Peacock JW; Jacobs WR; Frothingham R; Letvin NL; Liao HX; Haynes BF
Clin Vaccine Immunol; 2007 Jul; 14(7):886-93. PubMed ID: 17507541
[TBL] [Abstract][Full Text] [Related]
8. Development of a Live Recombinant BCG Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Gag Using a pMyong2 Vector System: Potential Use As a Novel HIV-1 Vaccine.
Kim BJ; Kim BR; Kook YH; Kim BJ
Front Immunol; 2018; 9():643. PubMed ID: 29636755
[TBL] [Abstract][Full Text] [Related]
9. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
Gómez CE; Abaitua F; Rodríguez D; Esteban M
Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8(+) T cells and antiviral protective immunity.
Shata MT; Hone DM
J Virol; 2001 Oct; 75(20):9665-70. PubMed ID: 11559798
[TBL] [Abstract][Full Text] [Related]
11. Recombinant pro-apoptotic Mycobacterium tuberculosis generates CD8+ T cell responses against human immunodeficiency virus type 1 Env and M. tuberculosis in neonatal mice.
Ranganathan UD; Larsen MH; Kim J; Porcelli SA; Jacobs WR; Fennelly GJ
Vaccine; 2009 Dec; 28(1):152-61. PubMed ID: 19808028
[TBL] [Abstract][Full Text] [Related]
12. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
13. A human immunodeficiency virus type 1 Env-granulocyte-macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine.
Rodr Guez D; Rodr Guez JR; Llorente M; V Zquez I; Lucas P; Esteban M; Mart Nez-A C; Del Real G
J Gen Virol; 1999 Jan; 80 ( Pt 1)():217-223. PubMed ID: 9934705
[TBL] [Abstract][Full Text] [Related]
14. Preclinical development of BCG.HIVA
Mahant A; Saubi N; Eto Y; Guitart N; Gatell JM; Hanke T; Joseph J
Hum Vaccin Immunother; 2017 Aug; 13(8):1798-1810. PubMed ID: 28426273
[TBL] [Abstract][Full Text] [Related]
15. A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice.
Shephard E; Burgers WA; Van Harmelen JH; Monroe JE; Greenhalgh T; Williamson C; Williamson AL
AIDS Res Hum Retroviruses; 2008 Feb; 24(2):207-17. PubMed ID: 18240963
[TBL] [Abstract][Full Text] [Related]
16. Optimizing HIV-1-specific CD8+ T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors.
Hopkins R; Bridgeman A; Bourne C; Mbewe-Mvula A; Sadoff JC; Both GW; Joseph J; Fulkerson J; Hanke T
Eur J Immunol; 2011 Dec; 41(12):3542-52. PubMed ID: 21932450
[TBL] [Abstract][Full Text] [Related]
17. Recombinant Mycobacterium smegmatis with a pMyong2 vector expressing Human Immunodeficiency Virus Type I Gag can induce enhanced virus-specific immune responses.
Kim BJ; Gong JR; Kim GN; Kim BR; Lee SY; Kook YH; Kim BJ
Sci Rep; 2017 Mar; 7():44776. PubMed ID: 28300196
[TBL] [Abstract][Full Text] [Related]
18. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
[TBL] [Abstract][Full Text] [Related]
19. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
[TBL] [Abstract][Full Text] [Related]
20. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.
AIDS Vaccine Evaluation Group 022 Protocol Team
J Infect Dis; 2001 Feb; 183(4):563-70. PubMed ID: 11170981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
